Vivos Therapeutics holder reports 9.25% equity stake
Vivos Therapeutics, Inc. has a significant shareholder group led by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife, which jointly report beneficial ownership of 1,812,031 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vivos Therapeutics, Inc. has a significant shareholder group led by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife, which jointly report beneficial ownership of 1,812,031 shares of common stock. This represents 9.25% of the outstanding common stock, with the calculation based on 19,570,972 shares outstanding as of August 10, 2026.
The reporting persons state they have sole voting and sole dispositive power over all 1,812,031 shares and no shared voting or dispositive power. Streeterville Capital LLC and Streeterville Management LLC are Utah limited liability companies, and John M. Fife is a United States citizen, with their principal business office in Chicago, Illinois.
Key Figures
Key Terms
beneficially owned financial
sole dispositive power financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Vivos Therapeutics (VVOS) does Streeterville Capital report owning?
Who are the reporting persons on this Schedule 13G for Vivos Therapeutics (VVOS)?
AI-generated analysis. How Rhea-AI works. Not financial advice.